Picture a 55-year-old earning $400,000 with $1.5 million in a traditional 401(k).

Investors need to pay close attention to RMD stock based on the movements in the options market lately.

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time).

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.

On May 11, 2026, ResMed Inc (RMD) shares fell 3.9% to a current price of $198.76. This decline comes amid broader market pressures, with the stock now trading c

Dividend growth stocks have a streak of at least 5 consecutive years of dividend increases. I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. To rank stocks, I do a quality assessment and sort candidates by quality scores. My new quality scoring system rates dividend stocks on a 10-point scale across 9 weighted factors. Each factor blends qualitative signals and quantitative metrics.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.

Revenue: $1.43 billion, an 11% increase year-over-year, 8% in constant currency.Gross Margin: 62.8%, increased by 290 basis points year-over-year.Operating Mar